{
    "id": 5864,
    "fullName": "GLI2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "GLI2 over exp indicates an over expression of the Gli2 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2736,
        "geneSymbol": "GLI2",
        "terms": [
            "GLI2",
            "CJS",
            "HPE9",
            "PHS2",
            "THP1",
            "THP2"
        ]
    },
    "variant": "over exp",
    "createDate": "05/07/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7261,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 inhibited proliferation of osteosarcoma cells with GLI2 overexpression in culture (PMID: 24151134).",
            "molecularProfile": {
                "id": 5694,
                "profileName": "GLI2 over exp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6265,
                    "pubMedId": 24151134,
                    "title": "Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24151134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7028,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 inhibited survival of multiple solid tumor cell lines with elevated GLI2 and SHH mRNA levels in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7015,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SANT1 inhibited survival of neuroblastoma cell lines with elevated GLI2 and SHH mRNA levels in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 3990,
                "therapyName": "SANT1",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7012,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SANT1 inhibited survival of Ewing sarcoma cell lines with elevated GLI2 and SHH mRNA in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 3990,
                "therapyName": "SANT1",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7022,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 inhibited survival of Ewing sarcoma cell lines with elevated GLI2 and SHH mRNA levels in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7023,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 inhibited survival of medulloblastoma cells with elevated GLI2 and SHH mRNA levels in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7018,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SANT1 inhibited survival of rhabdomyosarcoma cells with elevated GLI2 and SHH mRNA levels in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 3990,
                "therapyName": "SANT1",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7016,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SANT1 inhibited survival of medulloblastoma cells with elevated GLI2 and SHH mRNA levels in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 3990,
                "therapyName": "SANT1",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7029,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SANT1 inhibited survival of multiple solid tumor cell lines with elevated GLI2 and SHH mRNA levels in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 3990,
                "therapyName": "SANT1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7024,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 inhibited survival of rhabdomyosarcoma cells with elevated GLI2and SHH mRNA levels in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24358,
                "profileName": "GLI2 over exp SHH over exp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7146,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2334470 moderately inhibited growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 3662,
                "therapyName": "GSK2334470",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7143,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 did not inhibit growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7141,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3039478 efficiently inhibited survival of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7144,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PNU-74654 did not inhibit growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 2454,
                "therapyName": "PNU-74654",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7145,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nutlin-3 moderately inhibited growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7142,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC156529 efficiently inhibited survival of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 4085,
                "therapyName": "NSC156529",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7147,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3039478 and NSC156529 combination treatment resulted in improved growth inhibition over single drug treatment in primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 4383,
                "therapyName": "LY3039478 + NSC156529",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8109,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing wild-type Gli2 were resistant to Odomzo (sonidegib) in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26152,
                "profileName": "GLI2 over exp PTCH1 inact mut"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8108,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing wild-type Gli2 were resistant to Erivedge (vismodegib) in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26152,
                "profileName": "GLI2 over exp PTCH1 inact mut"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8107,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing wild-type Gli2 were resistant to LEQ506 in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26152,
                "profileName": "GLI2 over exp PTCH1 inact mut"
            },
            "therapy": {
                "id": 2416,
                "therapyName": "LEQ506",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 5694,
            "profileName": "GLI2 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 4433,
                    "name": "GLI1/2 inhibitor",
                    "profileName": "GLI2 over exp"
                }
            ]
        },
        {
            "id": 24358,
            "profileName": "GLI2 over exp SHH over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24497,
            "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26152,
            "profileName": "GLI2 over exp PTCH1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}